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and age; 3) sex, age and pre-surgery score of the outcome; and, 4) the
latter model plus BMI, education level, low back pain (LBP), depres-
sion, number of comorbidities, and symptomatic joint count. P values
of  0.05 were considered signiﬁcant. As change between 6 and 12
months surgery is known to be much less relative to baseline to 6
months, we conducted analyses at 12 months as a validation of the 6
month results.
Results: The sample included 323 females and 171 males. Females had
worse pain and function scores at baseline compared to males (pain:
39.0  16.5 in females versus 44.9  16.4 in males, p¼0.002; function:
47.7  18.6 in females versus 55.0  17.5 in males, p<0.0001). As well,
females had worse pain and function at follow-up (72.218.4 vs. 76.1
17.7, p¼0.03; 75.2  17.5 vs 80.5  17.1, p¼0.003, respectively). Females
also had worse pre-surgery depression scores (5.6  3.6 vs 4.7  3.2,
p¼0.006), higher rates of obesity (BMI >30: 54.2 vs. 36.3%, p¼0.0002),
and higher symptomatic joint count (>4: 61.3 vs. 44.4%, p¼0.0004).
Initially, regression ﬁndings suggested that females had worse out-
comes for pain (p¼0.04) and function (p¼0.007) compared to males.
However, this effect was lost once baseline pain/functional status were
also considered. In the ﬁnal model, worse outcomes were predicted by
pre-surgery pain/functional status, as well as depression, LBP and
comorbidity count. The results at 12months were consistent with those
at 6 months.
Conclusions: Women appear to have worse outcomes following TKR in
part as a function of their greater pain and more limited function pre-
surgery. However, depression and comorbidity, for which women have
worse status pre-surgery, further contribute to worse outcomes. These
ﬁnding suggest that women potentially could achieve comparable
outcomes tomen if surgery were performed before their symptoms and
disability became so severe. This could, in addition, limit the effect of
mood or, alternately, interventions to address mood could positively
inﬂuence outcomes.
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IDENTIFICATION OF SEROLOGICAL PROFILES ASSOCIATED WITH
TOTAL JOINT REPLACEMENT IN OSTEOARTHRITIS PATIENTS
R.H. Arends y, M.A. Karsdal z, A.C. Bay-Jensen z, D.S. Keller y. y Pﬁzer,
Groton, CT, USA; zNordic BioSci., Herlev, Denmark
Purpose: 1. To identify patients who will progress to requiring total
joint replacement (TJR) amongst a populationwith moderate-to severe-
osteoarthritis (OA) by measuring tissue speciﬁc biomarkers in serum
thus establishing a panel of prognostic biomarkers that may provide
molecular insight into the mechanism and pathology of the progression
of OA. 2. Investigate the effect of NSAIDs on the predictive and diag-
nostic serum proﬁle.
Methods: OA patients were randomly selected from clinical trials
investigating the anti-NGF therapeutic antibody tanezumab. Serum
samples from 240 patients who underwent a TJR (cases) and from 440
control OA patients who did not undergo TJR were used. Control group
consisted of w2 patients per case matched on: age (<65 or  65
years), Kellgren-Lawrence (K-L) grade, gender, BMI category (<30 or
30 kg/m2), OA severity (severe if both WOMAC Pain and Physical
function subscale scores were 7 and the Patient Global Assessment
score was 4 (i.e. Poor or Very Poor), otherwise baseline OA severity
was classiﬁed as not severe). On the average, the OA population was 62
years old, 80% K-L grade 3, females (68%), BMI w31 kg/m2, WOMAC
pain score of 7. Serum samples were analyzed for bone (Total Osteo-
calcin, CTX-I, DKK1, SOST), cartilage (C2M, COMP, PIIANP), connective
tissue (PINP, ICTP, C1M), synovial tissue (C3M), protease burden (MMP-
9) as well as inﬂammation markers (IL6, hsCRP, VEGF). Classiﬁcation
and Regression Tree analysis was used to identify biomarker
phenotypes.
Results: For NSAID and non-NSAID users separately, biomarker phe-
notypes were identiﬁed at baseline for patients predisposed for TJR. At
baseline, a biomarker combination for patients who used NSAIDs before
start of tanezumab clinical trials identiﬁed 96% of patients who
underwent a TJR and 61% of the patients who did not undergo a TJR.
Identiﬁcation of these biomarker phenotypes lowers the odds of a TJR
by 14-fold as compared to not having knowledge of the biomarkers. For
patients who did not use NSAIDs, 83% of patients who had a TJR and 63%
of the patients who did not undergo a TJR, were identiﬁed which lowers
the odds of a TJR by 3.6-fold. For patients who used NSAIDs con-
tinuously, 84% of patients who had a TJR and 77% of the patients whodid not have a TJR, were identiﬁed which lowers the odds of a TJR by
4.7-fold.
Conclusions: Serological biomarker proﬁles for predicting TJR were
identiﬁed irrespective of NSAID use and may assist in identifying
those patients whom will need a TJR. The proﬁles also suggest that
NSAID use increases the importance of the role of bone metabolism
in TJR pathology. The results need validation on other cohorts, and
may ﬁnally provide value to patients and payers in selecting the
most optimal treatment strategy for moderate-to-severe OA
patients.
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MALES ARE AT INCREASED RISK FOR SURGICAL COMPLICATIONS
FOLLOWING TOTAL JOINT ARTHOPLASTY
B. Ravi y, R. Croxford z, T. Leroux y, S. Hollands z, G. Hawker y. yUniv. of
Toronto, Toronto, ON, Canada; z Inst. for Clinical Evaluative Sci. (ICES),
Toronto, ON, Canada
Purpose: The burden of osteoarthritis of the hip and knee is higher
in females than in males. Despite this, there remains a gender dis-
parity in the recommendation and uptake of total joint arthroplasty
(TJA), with males being more likely to be offered surgery. This may
result from a perception that females have a higher rate of compli-
cations, including: acute myocardial infarction (AMI), venous
thrombo-embolism (VTE), infection, dislocation, early revision, and
death. To date, few studies have examined if differences by sex
persist in the rates of complications following TJA of the hip (THA) or
knee (TKA).
Methods: We deﬁned a cohort of patients who received their ﬁrst
primary elective THA or TKA between 2002-2009 utilizing admin-
istrative databases from Ontario, Canada. We excluded those who
received a primary or revision arthroplasty of the hip or knee prior to
April 1, 2002, those whose ﬁrst procedure was non-elective (e.g. for
cancer, fracture, or injury), or those with a history of hip dysplasia. We
compared baseline characteristics and rates of complications follow-
ing the index TJA for male and female recipients. Cox proportional
hazards were used to determine the relationship between sex and the
occurrence of speciﬁc complications (within 90d: VTE, AMI, mortality;
within 2y: dislocation, infection, and revision), deﬁned using vali-
dated algorithms, controlling for potential confounders (including
income quintile, rurality, and provider volume) and for clustering by
surgeons.
Results: Between April 1, 2002 and March 31, 2009, there were 97,445
patients who received their ﬁrst TJA (males: 41,023 - 42%; females:
56,422 - 58%). Compared with female TJA recipients, males were more
likely to have received a THA (43% versus 36%, p<0.001), more likely to
come from a rural area (20% versus 15%, p<0.001), and had greater co-
morbidity (Charlson score of 2þ: 5.5% vs 3.5%, p<0.001). Controlling for
these differences, and other potential confounders, male TJA recipients
were more likely to experience an infection (adjusted HR 1.41, 95%CI
1.24-1.61, p<0.0001), early revision (adjusted HR 1.24, 95%CI 1.10-1.40,
p¼0.0006), or death (adjusted HR 1.26, 95%CI 1.03-1.55, p¼0.03). They
were similarly likely to experience all other complications: dislocation
(adjusted HR 0.94, 95%CI 0.79-1.12, p¼0.48), AMI (adjusted HR 1.05, 95%
CI 0.93-1.19, p¼0.41), and VTE (adjusted HR 0.99, 95%CI 0.88-1.12,
p¼0.95).
Conclusions: In a population cohort undergoing their ﬁrst primary TJA,
male recipients were at increased risk for early revision, infection and
death relative to female recipients.
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BMP2 REQUIRES TGF-BETA TO INDUCE OSTEOPHYTES DURING
EXPERIMENTAL OA
E.N. Blaney Davidson, E.L. Vitters, A.B. Blom, A.P. van Caam,
M.B. Bennink, W.B. van den Berg, F.A. van de Loo, P.M. van der Kraan.
Radboud Univ. Med. Ctr., Nijmegen, Netherlands
Purpose: Osteophyte formation is one of the hallmarks of osteo-
arthritis (OA). We have shown that either overexpression of TGF-beta
or BMP2 can induce osteophytes in murine knee joints. However,
comparing osteophytes induced by experimental OA, TGF-beta or
BMP2 showed us that TGF-beta-induced osteophytes rather than
BMP2-induced osteophytes more closely resemble those observed in
experimental OA. TGF-beta-induced osteophytes develop mainly from
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with a more advanced chondrocyte-like phenotype as can found in the
growth plate. We additionally demonstrated that in mesenchymal
stem cells TGF-beta could induce chondrogenesis when BMP activity
was inhibited but not vice versa. This suggested that BMP2 requires an
alternative trigger, like TGF-beta, to induce the initiation of chondro-
genesis. We wanted to know whether this observation could be
extrapolated to osteophyte formation during experimental OA: Can
BMP2 induce osteophyte formation in experimental OAwhen TGF-beta
activity is blocked.
Methods: We made a unique transgenic mouse which expresses BMP2
under control of the Col2a1 promoter but only when exposed to
doxycycline (Col2a1-rtTA-BMP2). As a result, chondrocytes start to
produce BMP2 when this unique transgenic mouse is exposed to
doxycycline. We exposed these mice to doxycycline in food up to 8
weeks to investigate osteophyte formation in knee joints using his-
tology. In addition, we induced osteoarthritis by destabilization of the
medial meniscus (DMM-model), which amongst others results in
osteophyte formation, and investigated whether BMP2 augmented
osteophyte formation. Moreover, to investigate whether TGF-beta was
required for BMP2-related osteophyte formation we combined the
DMM-model with intra-articular injection of an adenovirus over-
expressing the speciﬁc TGF-beta inhibitor LAP with our without dox-
ycycline to overexpress BMP2. Murine knee joints were isolated 4
weeks after DMM exposure for histology to investigate effects on
osteophyte formation.
Results: Four out of 10 dox-treated Col2a1-rtTA-BMP2 mice had more
osteophytes than controls, but dox versus non-dox treated groups
were not signiﬁcantly different. When OA was induced, clearly
osteophytes developed with an average of 4.25 osteophytes per knee
joint. However, when these mice were treated with dox, thus induc-
ing chondrocyte-speciﬁc BMP2 expression in addition to OA, we
found a signiﬁcant increase in the number of osteophytes (8.0)
compared to DMM non-dox (Figure A, B). These “new” osteophytes
were much Iarger than regular DMM-induced osteophytes
(Figure A,C). The lack of osteophytes when treated with dox alone
compared to DMM with dox implied that the DMM treatment pro-
vided a trigger crucial for BMP2 to be able to aggravate osteophyte
formation. To investigate whether TGF-beta was that trigger we
inhibited TGF-beta inhibition by i.a. injection of Ad-LAP one day after
DMM-induction. This showed that without TGF-beta, BMP2 was no
longer capable of augmenting the number of osteophytes duringDMM as there were no signiﬁcant differences in osteophyte number
comparing DMM-Ad-LAP treated animals with or without dox
(Figure B,C). When focusing on the osteophytes that regularly develop
during DMM originating from the periost on the medial side of the
joint,we found an additional striking ﬁnding: the inhibition of TGF-
beta early during OA signiﬁcantly reduced the speed of osteophyte
formation which therefore were still in a chondrophyte at the
moment of sacriﬁce of the mice. This effect was completely abolished
by the additional presence of BMP2 which restored the osteophyte
maturation from chondrophyte to osteophyte.
Conclusions: Our data show that BMP2 is capable of inducing osteo-
phyte formation, but is dependent on an additional prior trigger to
achieve this, as present in OA. In OA conditions, BMP2 can severely
aggravate osteophyte formation, both in number and size. However,
when TGF-beta is blocked BMP2 is no longer capable of aggravating
osteophyte formation during DMM. Strikingly, early inhibition of TGF-
beta during OA impaired the speed of osteophyte formation, which
could be compensated by the presence of BMP2. Our data show for the
ﬁrst time that BMP2 is dependent on TGF-beta to induce de novo
osteophyte formation. This provides novel insight into the mechanism
behind osteophyte formation and provides clues for future therapeutic
application for osteophyte formation in OA.
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INHIBITION OF TGF-b1 ATTENUATES ARTICULAR CARTILAGE
DEGENERATION IN MATURE KNEE JOINTS OF MOUSE MODELS OF
OSTEOARTHRITIS
Y. Li y, R. Chen z, M. Mian z, M. Fu z, J. Zhao x, I. Golshirazian z,
B. Asbury z, L. Xu y. yHarvard Sch. of Dental Med. and Harvard Med. Sch.,
Boston, MA, USA; zHarvard Sch. of Dental Med., Boston, MA, USA; xUniv. of
California, Berkeley, Berkeley, CA, USA
Background: The goal of this study is to understand role of trans-
forming growth factor beta 1 (TGF-b1) in development of osteoarthritis
(OA). Results from studies indicate that the genetic inactivation of
Smad-3, or the disruption of the interaction of Tgf-b1 with its receptor
Tgf-b type II receptor (Tgfbr2), in germline cells results in OA-like knee
joints in mice at one month of age. However, other studies suggest that
the increased expression of Tgf-b1 in mature knee joints causes early
onset OA in animal models. Interestingly, a human genetic study reports
that a two-nucleotide deletion, 741-742del AT (nonsense mutation), in
SMAD-3 causes early-onset OA in one family. This human genetic study
also reports that a nucleotide change, 859C>T or 782C>T, in SMAD-3
increases the level of TGF-b1 and activity of the TGF-b1 signaling in two
families associated with early-onset OA. The observation in these
human families is consistent with the results from the animal models,
indicating that the lack of Tgf-b1 signaling in the germline cell results in
OA in developing joints and that increased Tgf-b1 signaling causes OA in
mature joints. The plausible explanation for this “conﬂicting” role of
TGF-b1 in the pathogenesis of OA is: effective TGF-b1 signaling acts in a
dose-dependent manner or a developmental stage-dependent manner.
The present study addresses the question as to whether inhibition of
Tgf-b1 signaling prevents mature knee joints from being degenerated in
mouse models of OA.
Method: 1) By use of conditional knock out techniques with aggrecan-
CreERt2 mice and ﬂoxed Tgfbr2 mice, Tgfbr2 was removed from artic-
ular cartilage of knee joints in mice at two months of age. Mice without
Tgfbr2 were kept for another 6 months or longer. Knee joints from the
mice (n¼4) and their corresponding control (n¼4) were then collected
for morphological analysis. 2) Type XI collagen-haploinsufﬁciency
(Col11a1þ/-) mice, a spontaneous mouse model of OA, were treated
with a neutralizing TGF-b1 antibody (25 mg) by intra-articular injection
into the knee joints at 2 months of age. An additional injection was
performed 2 weeks after the ﬁrst injection. Knee joints were collected
from mice at 6 months (n¼4) and control mice (n¼4) after the second
injection for morphological analysis. 3) Mice were subjected to desta-
bilization of the medial meniscus (DMM) or sham surgery. Immediately
following the surgery, the mice were treated with Losartan orally (0.6g/
1L drinking water) for 4 weeks (other studies indicate that Losartan
reduces the expression of Tgfbr2). The average intake of Losartan was
about 2.5mg/10g mouse body weight/day. Mice without the treatment
of Losartan served as controls. Mice were sacriﬁced at 8 weeks (n¼6)
following the surgery for collection of knee joints. 4) Mice without
Tgfbr2 at two months of age were subjected to DMM to induce articular
